Document is current
Any future updates will be listed below
-
Authors
Laverty, Daniel J.
Gupta, Shiv K. https://orcid.org/0000-0002-9107-9935
Bradshaw, Gary A. https://orcid.org/0000-0001-9724-6100
Hunter, Alexander S.
Carlson, Brett L.
Calmo, Nery Matias https://orcid.org/0009-0007-9677-2994
Chen, Jiajia
Tian, Shulan
Sarkaria, Jann N. https://orcid.org/0000-0001-7489-4885
Nagel, Zachary D. https://orcid.org/0000-0003-2104-2093
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (5P01CA092584)
U.S. Department of Health & Human Services | National Institutes of Health (P30ES000002, T32HL007118, U01CA227954, U19CA264362, U01CA227954)
American Cancer Society (RSG-22-038-01-DMC)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
Eagles 5th District Cancer Telethon- Cancer Research Fund
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
- License Information
-
More Information
Article History
Received: 20 December 2022
Accepted: 28 May 2024
First Online: 21 June 2024
Competing interests
: J.N.S. reports receiving commercial research grants from AbbVie, ABL Bio, ADC Therapeutics, AstraZeneca, Bayer, Black Diamond, Boehringer Ingelheim, Bristol Myers Squibb, Glaxo Smith Kline, Inhibrx, Karyopharm, ModifiBio, Otomagnetics, Rain Therapeutics, Reglagene, SKBP, Sumitomo Dainippon Pharma Oncology, and Wayshine. Z.D.N. is a co-inventor on a related patent (US 9,938,587 B2) and reports past unrelated sponsored research agreements with Pfizer Inc., Ensoma, Agios, and Intellia Therapeutics.
